Mizuho analyst Anthony Petrone resumed coverage of Medtronic (MDT) with an Outperform rating and $125 price target The firm says the company’s new product launches can drive is growth higher into fiscal 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic: Solid Quarter but Limited Growth Visibility Justifies Hold Rating
- AtriCure price target lowered to $53 from $64 at Canaccord
- Medtronic price target raised to $118 from $116 at Barclays
- Medtronic: Sustained Outperformance and Multi‑Year Growth Runway Driven by Cardiovascular and Robotics Pipelines
- Medtronic Earnings Call Highlights Growth and Margin Upside